Merck & Co.
Wikidi home Company Category Merck & Co.
Summary |
||
| Industry | ||
|---|---|---|
| Operating Income |
7,453,900,000
(2006-12-31, US$)
|
|
| Revenue | ||
| Number of employees |
61,500
(2005)
|
|
| Employees and other personnel | ||
| Date founded |
1889
|
|
| Headquarters |
One Merck Drive
(Whitehouse Station, NJ, 8,889)
?
(Readington)
ONE MERCK DR
(P O BOX 100, Whitehouse, 8,889, New Jersey)
|
|
Business Operation |
||
| Net profit | ||
| Total Assets |
47195700000.0
(2008-12-31, US$)
|
|
| Total Liabilities |
28437400000.0
(2008-12-31, US$)
|
|
| Competitive space |
Diabetic Neuropathy Treatment
Lateral Sclerosis Treatment
Cancer treatment
|
|
| Current Assets |
19304900000.0
(2008-12-31, US$)
|
|
| Current Liabilities |
14318700000.0
(2008-12-31, US$)
|
|
| Cash |
4,368,300,000
(2008-12-31, US$)
|
|
| Retained Earnings |
43698800000.0
(2008-12-31, US$)
|
|
Issuer |
||
| Issue | ||
Ranked item |
||
| Appears in ranked lists |
|
|
Customer |
||
| Supplier | ||
Consumer company |
||
| Products |
|
|
Drug manufacturer |
||
| Drugs manufactured |
Cancidas 5 lyophilized powder for injectable solution
(Cancidas, United States of America, no, 2001-01-26, 2015-07-26, 2010-06-01, dailymed.nlm.nih.gov, NDA021227, no, 0006-3822)
Singulair 5 chewable tablet
(Singulair, United States of America, no, 1998-02-20, US Patent 5565473, 2012-08-03, Montelukast sodium 5 chewable tablet, 2012-03-26, Pink, Circle, 10, 1, MSD;275;SINGULAIR, dailymed.nlm.nih.gov, NDA020830, no, 0006-9275, Cherry)
Isentress 25 chewable tablet
(Raltegravir, United States of America, no, 2011-12-21, US Patent 7754731, 2029-03-11, 2012-03-28, Yellow, Circle, 8, 1, Merck;logo;473, dailymed.nlm.nih.gov, NDA203045, no, 0006-0473)
|
|
BV: Venture Investor |
||
| Investment Round |
Burrill & Company, HBM BioVentures AG, HealthCap
(2008-10-08, Odyssey Thera)
|
|
Publisher |
||
| Book editions published | ||
Author |
||
| Works written | ||
Organization |
||
| Legal structure | ||
| Place founded | ||
| Organizations acquired |
Schering-Plough
(2009-11)
|
|
| Founders | ||
| Board members |
|
|
| Spun off from |
Merck KGaA
(1917)
|
|
| Spin offs | ||
| Child |
Merial Korea Ltd
(2005, 2006, 2007, 2008, 2009)
Merck Frosst Canada Ltd
(2004, 2005, 2006, 2007, 2008, 2009)
Merck HDAC Research LLC
(2007, 2008, 2009)
|
|
| Leadership |
Exec. V.P. & C.F.O
(Peter N. Kellogg, 2009)
Exec. V-P and Pres., MRL
(Peter S. Kim, 2009)
Vice President and Treasurer
(Mark E Mcdonough, 2009)
|
|
| Phone number |
United States of America
((908) 423-1000, 1, Customer service)
|
|
Science or Technology Company |
||
| Medical focus | ||
| Products | ||
| Technology Focus | ||
Architectural structure owner |
||
| Structures Owned | ||
